It depends on the standard you follow. As of September 2026, McKesson Corporation (MCK) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.27% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.86% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 8.27% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.86% / 33% · Receivables / Mkt Cap (36m) 27.7% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones Islamic | Debt / Mkt Cap (24m) 8.27% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.86% / 33.33% · Receivables / Mkt Cap (24m) 27.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 9.18% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.37% / 33.33% · Receivables / Avg Assets (4Q) 33.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 9.97% / 33.33% · (Cash+ST Inv) / Total Assets 7.07% / 33.33% · (Cash+Recv) / Total Assets 40.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, McKesson Corporation (MCK) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones Islamic, and fails MSCI and FTSE.
Yes. McKesson Corporation is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
McKesson Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
McKesson Corporation (NYSE: MCK) is a Healthcare company (Medical - Distribution) with a market capitalization of $127.6B. The Maz Rating grades it against the other companies in its sector.
McKesson Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $1105.04, McKesson Corporation trades at 28.3x trailing earnings and 0.3x sales, with an EV/EBITDA of 17.5. Over the last twelve months it generated about $418.8B of revenue and $4.5B of net income. It runs a gross margin of 3.7%, an operating margin of 1.6% and a net margin of 1.1%. It shows return on equity of -161.2%, return on invested capital of 29.3% and a free cash flow yield of 5.4%. On the balance sheet: a debt-to-equity ratio of -2.82 and a current ratio of 0.90. Over the past 52 weeks the share price ranged from $723.68 to $1121.50, with a beta of 0.28.
McKesson Corporation pays a dividend yielding 0.31%, with 9% of earnings paid out. Its Maz Dividend Score is 4.83 out of 5, ranked against the other dividend payers in its sector (Safety 4.63, Growth 4.63, Yield 1.70, Consistency 4.29).
31 Wall Street analyst ratings cover the stock: 1 Strong Buy, 24 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.